Blocking EGFR with nimotuzumab: a novel strategy for COVID-19 treatment

Background: Lung injury and STAT1 deficit induce EGFR overexpression in SARS-CoV-2 infection. Patients & methods: A phase I/II trial was done to evaluate the safety and preliminary effect of nimotuzumab, an anti-EGFR antibody, in COVID-19 patients. Patients received from one to three infusions t...

Descripción completa

Detalles Bibliográficos
Autores principales: Londres, Henrry Diaz, Armada, Jorge Jiménez, Martínez, Aray Hernández, Abdo Cuza, Anselmo A, Sánchez, Yamilka Hernández, Rodríguez, Aylin Granado, Figueroa, Sarahy Sepúlveda, Llanez Gregorich, Egda M, Torres Lahera, Mery L, Peire, Francisco Gómez, González, Teresita Montero, González, Yaneth Zamora, Añé Kouri, Ana L, Palomo, Addys González, Concepción, Mayelin Troche, Pérez, Loipa Medel, Luaces-Alvarez, Patricia Lorenzo, Iglesias, Daymys Estévez, Hernández, Danay Saavedra, Suzarte, Mayra Ramos, Ramos, Tania Crombet
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Future Medicine Ltd 2022
Materias:
Preliminary Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8936166/
https://www.ncbi.nlm.nih.gov/pubmed/35306855
http://dx.doi.org/10.2217/imt-2022-0027

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8936166/
https://www.ncbi.nlm.nih.gov/pubmed/35306855
http://dx.doi.org/10.2217/imt-2022-0027

Ejemplares similares